Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-09-27 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is titled 'Company Announcement' and details a specific corporate event: the approval of DARZALEX in Japan and the associated milestone payment. It is a formal communication intended for investors and the public regarding a significant business development (drug approval and financial impact). This type of announcement, which is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV), fits best under the general category for corporate news releases. Since it is a formal announcement of a business event, and not a general regulatory filing fallback (RNS) or a report publication announcement (RPA), it is classified as a Regulatory Filing (RNS) as the most appropriate general category for significant, non-standardized corporate news releases that don't fit the other specific types, although it functions like an Earnings Release (ER) in terms of timing, it is not explicitly reporting period results. Given the options, RNS serves as the best catch-all for significant, non-periodic corporate news that isn't a specific financial report or management change.
2017-09-27 English
Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the regulatory approval of a drug (DARZALEX) in Japan. It provides details on the approval, milestone payments, and background information on the drug and the company. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication notice (RPA). As it is a general regulatory/corporate announcement, it falls under the RNS (Regulatory Filings) category.
2017-09-27 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory disclosure requirements. This falls directly under the category of share issues and capital changes.
2017-09-26 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 90% confidence The document is a company announcement detailing an increase in share capital due to the exercise of employee warrants, specifying the number of newly issued shares, subscription prices, proceeds, and the impact on total share capital. This is a capital structure change announcement rather than a full report or regulatory filing. It clearly falls under Share Issue/Capital Change (SHA).
2017-09-26 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is titled "Company Announcement" and details a significant business development: Seattle Genetics exercising an option to co-develop and co-commercialize tisotumab vedotin with Genmab, including sharing costs and profits 50:50. This is a strategic partnership announcement, not a routine financial filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a press release announcing a material event. Since there is no specific category for 'Partnership Announcement' or 'Press Release', and it is not a report itself, the most appropriate general category for a significant, non-standard corporate disclosure that is not covered by other specific codes (like M&A, Capital Change, or Director Dealing) is the general Regulatory Filings fallback category (RNS), as these types of announcements are typically filed via RNS or similar regulatory news services.
2017-08-29 English
Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors
Regulatory Filings Classification · 78% confidence The document is a corporate press release announcing that Seattle Genetics has exercised its co-development option for tisotumab vedotin under an existing collaboration agreement, outlining the commercial terms and forward-looking statements. It is not a financial report, earnings release, M&A transaction, or management change notice, but a general regulatory announcement. Therefore, it falls under the catch-all Regulatory Filings category (RNS).
2017-08-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.